Who Paid My Doc Search
Menu
Organisation paid for research Program year 2023 Source: CMS Open Payments

MDH Research LLC

Neither a doctor nor a teaching hospital

Research payments

$2,079,720

182 payments

Through program year 2023, MDH Research LLC is reported as receiving $2,079,720 in research payments, across 182 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $727 3
2022 Research $10,082 3
2021 Research $1,125,720 8
2020 Research $417,992 14
2019 Research $525,199 154

Breakdown

Who paid Research payments · program years 2019–2023
  1. Novartis Pharmaceuticals Corporation $1,529,225 14 payments
  2. Eisai Inc. $233,992 140 payments
  3. Genzyme Corporation $153,016 11 payments
  4. F. Hoffmann-La Roche AG $76,054 10 payments
  5. Celgene Corporation $45,869 1 payment
  6. Genentech, Inc. $30,063 2 payments
  7. EMD Serono, Inc. $6,000 3 payments
  8. Roche Products Limited $5,500 1 payment
Studies the money was for Research payments · program years 2019–2023
  1. A Single-Arm, Prospective, Multi-Center Study to Explore Maintained Efficacy With Ofatumumab Therapy in Patients With Relapsing Multiple Sclerosis Who Discontinue Intravenously Delivered Anti-Cd20 Monoclonal Antibody (Acd20 Mab) Therapy (Olikos) $1,075,262 2 payments
  2. A Single-Arm, Prospective, Multicentre, Open-Label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate Or Fingolimod Therapy $239,941 2 payments
  3. A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $233,992 140 payments
  4. Exploring the Safety and Tolerability of Conversion to Dose Titrated Siponimod in Patients With Relapsing Forms of Multiple Sclerosis A 6 Month Open Label Multi Center Phase III B Study Expanded $93,280 1 payment
  5. A Randomized Double Blind Double Dummy Parallel Group Study Comparing the Efficacy and Safety of Ofatumumab Administered Subcutaneously Versus Teriflunomide Administered Orally in Patients With Relapsing Forms of Multiple Sclerosis $83,886 2 payments
  6. Second Phase III in RMS $76,054 10 payments
  7. A Phase 2b Dose-finding Study for SAR442168, a Bruton's Tyrosine Kinase Inhibitor, in Participants With Relapsing Multiple Sclerosis $64,317 1 payment
  8. PhIII Efficacy And Safety of RPC1063 in Relapsing MS (RPC01-3001) (RPC01-3001) $45,869 1 payment
  9. Long-term Extension Safety and Efficacy Study of SAR442168 in Participants With Relapsing Multiple Sclerosis $35,542 4 payments
  10. Ocrelizumab Vaccination Study $30,063 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record